<i>IDH1/2</i> mutations in acute myeloid leukemia

Byun, Ja Min; Yoo, So Young; Kim, Hyeong-Joon; Ahn, Jae‐Sook; Koh, Youngil; Jang, Jun Ho; Yoon, Sung‐Soo

doi:10.5045/br.2021.2021152

Cited by 8 publications

(4 citation statements)

References 42 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study found that patients with IDH1/IDH2 -mutated AML had favorable outcomes when treated with HMAs and venetoclax [ 34 ]. Our data may provide additional evidence to recommend HMAs combined with venetoclax or IDH1/ IDH2 inhibitors because it is difficult to expect improved survival with HMAs alone in elderly AML patients with IDH1/ IDH2 mutations [ 35 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine

Kim

Ahn

et al. 2023

Korean J Intern Med

Self Cite

View full text Add to dashboard Cite

Background/Aims: We evaluated the role of next-generation sequencing (NGS)-based disease monitoring for elderly patients diagnosed with acute myeloid leukemia (AML) who received decitabine therapy.Methods: A total of 123 patients aged > 65 years with AML who received decitabine were eligible. We analyzed the dynamics of variant allele frequency (VAF) in 49 available follow-up samples after the fourth cycle of decitabine. The 58.6% VAF clearance (Δ, [VAF at diagnosis − VAF at follow-up] × 100 / VAF at diagnosis) was the optimal cut-off for predicting overall survival (OS).Results: The overall response rate was 34.1% (eight patients with complete remission [CR], six of CR with incomplete hematologic recovery, 22 with partial responses, and six with morphologic leukemia-free status). Responders (n = 42) had significantly better OS compared with non-responders (n = 42) (median, 15.3 months vs. 6.5 months; p < 0.001). Of the 49 patients available for follow-up targeted NGS analysis, 44 had trackable gene mutations. The median OS of patients with ΔVAF ≥ 58.6% (n=24) was significantly better than that of patients with ΔVAF < 58.6% (n = 19) (20.5 months vs. 9.8 months, p = 0.010). Moreover, responders with ΔVAF ≥ 58.6% (n = 20) had a significantly longer median OS compared with responders with VAF < 58.6% (n = 11) (22.5 months vs. 9.8 months, p = 0.004).Conclusions: This study suggested that combining ΔVAF ≥ 58.6%, a molecular response, with morphologic and hematologic responses can more accurately predict OS in elderly AML patients after decitabine therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine

Kim

Ahn

et al. 2023

Korean J Intern Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Gene panels target curated sets of genes associated with specific clinical phenotypes such as acute leukemia, MDS, and lymphoma. Sequencing aims to identify DNA SNVs that are confidently associated with the presenting disease [ 33 ]. NGS data allowed the detection of CNVs from targeted gene panels.…”

Section: Advances In Genomic Technologiesmentioning

confidence: 99%

Genomic technologies for detecting structural variations in hematologic malignancies

Jang

2024

Blood Res.

View full text Add to dashboard Cite

Genomic structural variations in myeloid, lymphoid, and plasma cell neoplasms can provide key diagnostic, prognostic, and therapeutic information while elucidating the underlying disease biology. Several molecular diagnostic approaches play a central role in evaluating hematological malignancies. Traditional cytogenetic diagnostic assays, such as chromosome banding and fluorescence in situ hybridization, are essential components of the current diagnostic workup that guide clinical care for most hematologic malignancies. However, each assay has inherent limitations, including limited resolution for detecting small structural variations and low coverage, and can only detect alterations in the target regions. Recently, the rapid expansion and increasing availability of novel and comprehensive genomic technologies have led to their use in clinical laboratories for clinical management and translational research. This review aims to describe the clinical relevance of structural variations in hematologic malignancies and introduce genomic technologies that may facilitate personalized tumor characterization and treatment.

show abstract

“…Another area of research is the identification of genetic mutations in AML that can be targeted with precision medicine. Mutations in genes such as IDH1/2 have been identified in AML and have become targets for precision medicine approaches [29]. Additionally, pharmacogenomic profiling has been used to identify therapeutic vulnerabilities in pediatric AML, which can inform personalized treatment strategies [30].…”

Section: Recent Advances In the Treatment Of Acute Myeloid Leukemiamentioning

confidence: 99%

Advancements in Myeloid Leukemia Treatment: A Comprehensive Update

Buhari,

Muhammad,

Obeagu

2023

IAA JBS

View full text Add to dashboard Cite

This comprehensive update explores the recent advancements in the treatment landscape of myeloid leukemia. Myeloid leukemia, a heterogeneous group of hematological malignancies, poses significant challenges in clinical management. This review highlights the latest therapeutic approaches, including targeted therapies, immunotherapies, and emerging treatment modalities. It discusses the impact of precision medicine, novel drug developments, and the evolving role of immunotherapy in managing myeloid leukemia. Furthermore, the abstract outlines current research trends, challenges, and future prospects, aiming to provide a concise overview for healthcare professionals and researchers involved in leukemia management. Keywords: targeted therapy; immunotherapy; precision medicine; molecular profiling; personalized treatment; bone marrow transplantation; novel therapies

show abstract

IDH1/2 mutations in acute myeloid leukemia

Cited by 8 publications

References 42 publications

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine

Genomic technologies for detecting structural variations in hematologic malignancies

Advancements in Myeloid Leukemia Treatment: A Comprehensive Update

Contact Info

Product

Resources

About